APO-DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
11-01-2023
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DIMETHYL FUMARATE
Tillgänglig från:
APOTEX INC
ATC-kod:
L04AX07
INN (International namn):
DIMETHYL FUMARATE
Dos:
240MG
Läkemedelsform:
CAPSULE (DELAYED RELEASE)
Sammansättning:
DIMETHYL FUMARATE 240MG
Administreringssätt:
ORAL
Enheter i paketet:
15G/50G
Receptbelagda typ:
Prescription
Terapiområde:
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0154210002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2021-10-04
Produktens egenskaper
_APO-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules) _
_Page 1 of 37 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
APO-DIMETHYL FUMARATE
Dimethyl Fumarate Delayed-Release Capsules
Delayed-Release Capsules, 120 mg and 240 mg, Oral
Antineoplastic and Immunomodulating Agents
Apotex Inc.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
October 04, 2021
Date of Revision:
January 11, 2023
Submission Control Number: 266551
_APO-DIMETHYL FUMARATE (dimethyl fumarate delayed-release capsules) _
_Page 2 of 37 _
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.1 Pediatrics
01/2023
2 CONTRAINDICATIONS
01/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
01/2023
7 WARNINGS AND PRECAUTIONS, Hematologic
01/2023
7 WARNINGS AND PRECAUTIONS, Immune
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
........................................................................................................2
TABLE OF CONTENTS
..........................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................4
1
INDICATIONS
.............................................................................................................................4
1.1
Pediatrics
.......................................................................................................................................
4
1.2
Geriatrics
.......................................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................................4
4
DOSAGE AND ADMINISTRATION
.................................................................................................4
4.
Läs hela dokumentet
